Free Online CME

Riding the Wave: Clinical Management of Myeloid
Malignancies in an Era of Novel Therapies

Print this Content

 

Riding the Wave:  Clinical Management of Myeloid Malignancies in an Era of Novel Therapies online series will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloid malignancies.

Webcasts


Jae Park, MD
Release Date: January 17, 2019
Expiration Date: January 17, 2021
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: Flash Player
Specialties:  Oncology, Hematology
Jamile Shammo, MD
Step into (Dark) Liquid: PNH
Jamile Shammo, MD
Release Date: January 17, 2019
Expiration Date: January 17, 2021
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: Flash Player
Specialties:  Oncology, Hematology
Luca Malcovati, MD
Release Date: January 17, 2019
Expiration Date: January 17, 2021
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: Flash Player
Specialties:  Oncology, Hematology
John Mascarenhas, MD
Release Date: January 17, 2019
Expiration Date: January 17, 2021
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: Flash Player
Specialties:  Oncology, Hematology
Steve Gore, MD
Release Date: January 17, 2019
Expiration Date: January 17, 2021
Estimated Time: 15 minutes
Type:  Webcast
Technical Requirements: Flash Player
Specialties:  Oncology, Hematology
Matt Kalaycio, MD
Release Date: January 17, 2019
Expiration Date: January 17, 2021
Estimated Time: 15 minutes
Type:  Webcast
Technical Requirements: Flash Player
Specialties:  Oncology, Hematology

 

Series Learning Objectives

  • Critically appraise results of research on the evolving role of chimeric antigen receptor-T cell (CAR-T) therapy in myeloid malignancies.

  • Provide an in-depth overview of the efficacy and side effects of combination therapies for acute myeloid leukemia.

  • Summarize the prognostic implications and treatment considerations for idiopathic cytopenia of undetermined significance (ICUS), clonal hematopoiesis of indeterminate potential (CHIP), and clonal cytopenias of undetermined significance (CCUS).

  • Describe the diagnostic complexities and treatment options for paroxysmal nocturnal hemoglobinuria (PNH).

  • Describe the genomic mutations in overlap syndromes, prognostic implications, and treatment options.

  • Identify the most recent indications and strategies for bone marrow transplant in patients with acute myeloid leukemia or myelodysplastic syndrome.

Target Audience

This educational activity is designed for an international audience including medical oncologists/hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program.

Activity Director

Matt Kalaycio, MD 
Chair, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education,
Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.